Patrik Brundin Laboratory

Selected Publications

Bacelis J, Compagno M, George S, Pospisilik A, Brundin P, Torinsson A, Brundin L. 2021. Decreased risk of Parkinson’s disease after rheumatoid arthritis diagnosis: a nested case-control study with matched cases and controls. J Parkinson’s Dis.

Li P, Killinger BA, Ensink E, Beddows I, Yilmaz A, Lubben N, Lamp J, Schilthuis M, Vega IE, Woltjer R, Pospisilik JA, Brundin P, Brundin L, Graham SF, Labrie V. 2021. Gut microbiota dysbiosis is associated with elevated bile acids in Parkinson’s disease. Metabolites 11(1):29.

Brundin P, Nath A, Beckham JD. 2020. Is COVID-19 a perfect storm for Parkinson’s disease?  Trends Neurosci.

Chatterjee D, Sanchez DS, Quansah E, Rey NL, George S, Becker K, Madaj Z, Steiner JA, Ma J, Escobar Galvis ML, Kordower JH, Brundin P. 2019. Loss of one engrailed1 allele enhances induced alpha-synucleinopathy.  J Parkinsons Dis 9(2):315–326.

Brundin P, Coetzee GA. 2019. Genetically engineered stem cell-derived neurons can be rendered resistant to alpha-synuclein aggregate pathology. Eur J Neurosci.

Johnson ME, Stecher B, Labrie V, Brundin L, Brundin P. 2018. Triggers, facilitators and aggravators: Redefining Parkinson’s disease pathogenesis. Trends Neurosci.

Brundin P, Wyse R. 2018. Cancer enzyme affects Parkinson’s disease. Science 362(6414):521-522.

Killinger BA*, Madaj Z*, Sikora JW, Rey N, Haas AJ, Vepa Y, Lindqvist D, Chen H, Thomas PM, Brundin P, Brundin L, Labrie V. 2018. The veriform appendix impacts the risk of developing Parkinson’s. Sci Transl Med 10(465):eaar5280.

Graham SF, Rey NL, Yilmaz A, Kumar P, Madaj Z, Maddens M, Bahado-Singh RO, Becker K, Schulz E, Meyerdirk LK, Steiner JA, Ma J, Brundin P. 2018. Biochemical profiling of the brain and blood metabolome in a mouse model of prodromal Parkinson’s disease reveal distinct metabolic profilesJ Proteome Res doi: 10.1021/acs.jproteome.8b00224. 

Quansah E*, Peelaerts W*, Langston JW, Simon DK, Colca J, Brundin P. 2018. Targeting energy metabolism via the mitochondrial pyruvate carrier as a novel approach to attenuate neurodegenerationMol Neurodegener 13:28.     
*Contributed equally

Rey NL, Wesson DW, Brundin P. 2018. The olfactory bulb as the entry site for prion-like propagation in neurodegenerative diseasesNeurobiol Dis 109(B):226–248.  

Rey NL, George S, Steiner JA, Madaj Z, Luk KC, Trojanowski JQ, Lee VM, Brundin P. 2017. Spread of aggregates after olfactory bulb injection of α-synuclein fibrils is associated with early neuronal loss and is reduced long termActa Neuropathol 135(1):65–83.

Thirtamara-Rajamani K, Li P, Escobar Galvis ML, Labrie V, Brundin P, Brundin L. 2017. Is the enzyme ACMSD a novel therapeutic target in Parkinson’s disease? J Parkinson Dis 7(4):577–587.     

Ghosh A, Tyson T, George S, Hildebrandt EN, Steiner JA, Madaj Z, Schulz E, Machiela E, McDonald WG, Escobar Galvis ML, Kordower JH, Van Raamsdonk JM, Colca JR, Brundin P. 2016. Mitochondrial pyruvate carrier regulates autophagy, inflammation and neurodegeneration in experimental models of Parkinson’s diseaseSci Transl Med 8(368):368ra174.     

Coetzee SG, Pierce S, Brundin P, Brundin L, Hazelett DJ, Coetzee GA. 2016. Enrichment of risk SNPs in regulatory regions implicate diverse tissues in Parkinson’s disease etiologySci Rep 6:30509. 

Brundin P, Wyse R. 2015. Parkinson disease: laying the foundations for disease-modifying therapies in PDNat Rev Neurol 11(10):553–555.   

George S, Brundin P. 2015. Immunotherapy in Parkinson’s disease: micromanaging alpha-synuclein aggregationJ Parkinsons Dis 5(3):413–424.     

Grey M, Dunning CJ, Gaspar R, Grey C, Brundin P, Sparr E, Linse S. 2015. Acceleration of α-synuclein aggregation by exosomesJ Biol Chem 290(5):2969–2982.  

Nordström U, Beauvais G, Ghosh A, Sasidharan BCP, Lundblad M, Fuchs J, Joshi RL, Lipton JW, Roholt A, Medicetty S, Feinstein TN, Steiner JA, Galvis MLE, Prochiantz A, Brundin P. 2015. Progressive nigrostriatal terminal dysfunction and degeneration in the engrailed1 heterozygous mouse model of Parkinson’s diseaseNeurobiol Dis 73(1):70–82.    

Reyes JF, Rey NL, Bousset L, Melki R, Brundin P, Angot E. 2014. Alpha-synuclein transfers from neurons to oligodendrocytesGlia 62(3):387–398.    

Rey NL, Petit GH, Bousset L, Melki R, Brundin P. 2013. Transfer of human α-synuclein from the olfactory bulb to interconnected brain regions in miceActa Neuropathol 126(4):555–573.     

Burguillos MA, Deierborg T, Kavanagh E, Persson A, Hajji N, Garcia-Quintanilla A, Cano J, Brundin P, Englund E, Venero JL, Joseph B. 2011. Caspase signalling controls microglia activation and neurotoxicityNature 472(7343):319–324.               

Hansen C, Angot E, Bergström AL, Steiner JA, Pieri L, Paul G, Outeiro TF, Melki R, Kallunki P, Fog K, Li JY, Brundin P. 2011. Alpha-synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cellsJ Clin Invest 121(2): 715–725.        

Angot E, Steiner JA, Hansen C, Li JY, Brundin P. 2010. Are synucleinopathies prion-like disorders? Lancet Neurol 9(11):1128–1138.

Brundin P, Melki R, Kopito R. 2010. Prion-like transmission of protein aggregates in neurodegenerative diseasesNat Rev Mol Cell Biol 11(4):301–307.      

Brundin P, Li JY, Holton JL, Lindvall O, Revesz T. 2008. Research in motion: the enigma of Parkinson’s disease pathology spreadNat Rev Neurosci 9(10):741–745.         

Li JY, Englund E, Holton JL, Soulet D, Hagell P, Lees AJ, Lashley T, Quinn NP, Rehncrona S, Björklund A, Widner H, Revesz T, Lindvall O, Brundin P. 2008. Lewy bodies in grafted neurons in subjects with Parkinson’s disease suggest host-to-graft disease propagationNat Med 14(5):501–503.   

Ciechanover A, Brundin P. 2003. The ubiquitin proteasome system in neurodegenerative diseases: sometimes the chicken, sometimes the eggNeuron 40(2):427–446.   

Lotharius J, Brundin P. 2002. Pathogenesis of Parkinson’s disease: dopamine, vesicles and alpha-synucleinNat Rev Neurosci 3(12):932–942.        

Brundin P, Pogarell O, Hagell P, Piccini P, Widner H, Schrag A, Kupsch A, Crabb L, Odin P, Gustavii B, Björklund A, Brooks DJ, Marsden CD, Oertel WH, Quinn NP, Rehncrona S, Lindvall O. 2000. Bilateral caudate and putamen grafts of embryonic mesencephalic tissue treated with lazaroids in Parkinson’s diseaseBrain 123(Pt 7):1380–1390.       

Hagell P, Schrag A, Piccini P, Jahanshahi M, Brown R, Rehncrona S, Widner H, Brundin P, Rothwell JC, Odin P, Wenning GK, Morrish P, Gustavii B, Björklund A, Brooks DJ, Marsden CD, Quinn NP, Lindvall O. 1999. Sequential bilateral transplantation in Parkinson’s disease: effects of the second graftBrain 122(Pt 6):1121–1132.              

Hansson O, Petersén A, Leist M, Nicotera P, Castilho RF, Brundin P. 1999. Transgenic mice expressing a Huntington’s disease mutation are resistant to quinolinic acid-induced striatal excitotoxicityProc Natl Acad Sci U S A 96(15):8727–8732.    

Schierle GS, Hansson O, Leist M, Nicotera P, Widner H, Brundin P. 1999. Caspase inhibition reduces apoptosis and increases survival of nigral transplantsNat Med5(1):97–100.           

Brundin P, Björklund A. 1998. Survival of expanded dopaminergic precursors is critical for clinical trialsNat Neurosci 1(7):537.  

Nakao N, Frodl EM, Widner H, Carlson E, Eggerding FA, Epstein CJ, Brundin P. 1995. Overexpressing Cu/Zn superoxide dismutase enhances survival of transplanted neurons in a rat model of Parkinson’s diseaseNat Med 1(3):226–231.    

Nakao N, Frodl EM, Duan WM, Widner H, Brundin P. 1994. Lazaroids improve the survival of grafted rat embryonic dopamine neuronsProc Natl Acad Sci U S A 91(26):12408–12412.              

Horellou P, Brundin P, Kalén P, Mallet J, Björklund A. 1990. In vivo release of dopa and dopamine from genetically engineered cells grafted to the denervated rat striatumNeuron 5(4):393–402.    

Lindvall O, Brundin P, Widner H, Rehncrona S, Gustavii B, Frackowiak R, Leenders KL, Sawle G, Rothwell JC, Marsden CD, et al. 1990. Grafts of fetal dopamine neurons survive and improve motor function in Parkinson’s diseaseScience 247(4942):574–577.           

Wictorin K, Brundin P, Gustavii B, Lindvall O, Björklund A. 1990. Reformation of long axon pathways in adult rat central nervous system by human forebrain neuroblastsNature 347(6293):556–558.